Genprex’s Reqorsa gene therapy secures another FDA fast-track designation
Genprex has announced that the FDA has granted fast-track designation for Reqorsa, its small cell lung cancer (SCLC) therapy.
Genprex has announced that the FDA has granted fast-track designation for Reqorsa, its small cell lung cancer (SCLC) therapy.
What's Your Reaction?
